Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Pemoline treatment of adolescents with attention deficit hyperactivity disorder: A short-term controlled trial
Autore:
Bostic, JQ; Biederman, J; Spencer, TJ; Wilens, TE; Prince, JB; Monuteaux, MC; Sienna, M; Polisner, DA; Hatch, M;
Indirizzi:
Harvard Univ, Massachusetts Gen Hosp, Sch Med, Pediat Psychopharmacol Unit, Boston, MA 02114 USA Harvard Univ Boston MA USA 02114 ychopharmacol Unit, Boston, MA 02114 USA
Titolo Testata:
JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY
fascicolo: 3, volume: 10, anno: 2000,
pagine: 205 - 216
SICI:
1044-5463(200023)10:3<205:PTOAWA>2.0.ZU;2-D
Fonte:
ISI
Lingua:
ENG
Soggetto:
MINIMAL BRAIN-DYSFUNCTION; DOUBLE-BLIND; PSYCHIATRIC STATUS; CHILDREN; ADULTS; METHYLPHENIDATE; ADHD; STIMULANTS; THERAPY; PLACEBO;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
60
Recensione:
Indirizzi per estratti:
Indirizzo: Bostic, JQ Harvard Univ, Massachusetts Gen Hosp, Sch Med, Pediat Psychopharmacol Unit, WAC 725, Boston, MA 02114 USA Harvard Univ WAC 725 Boston MA USA 02114 , Boston, MA 02114 USA
Citazione:
J.Q. Bostic et al., "Pemoline treatment of adolescents with attention deficit hyperactivity disorder: A short-term controlled trial", J CH AD PSY, 10(3), 2000, pp. 205-216

Abstract

Background: Despite the increased recognition of attention deficit hyperactivity disorder (ADHD) in adolescents, few controlled studies have assessedtreatments for this age group. Adolescent issues, such as embarrassment atreceiving medication at school and experimentation with abusable substances, have accelerated efforts to find effective, well-tolerated treatments beyond traditional stimulants. Pemoline has been found effective for treatingboth children and adults with ADHD but has not been evaluated in adolescents with ADHD. Methods: Twenty-one adolescents (mean age 14 years old) diagnosed with ADHD by structured and clinical interviews participated in a 10-week, double-blind crossover design study of pemoline. Dosing was optimized with robust doses up to 3 mg/kg/day in one to two doses. Clinical evaluations of ADHD, depression, anxiety, and oppositional defiant disorder (ODD) symptoms were assessed weekly. Results: Adolescents with ADHD exhibited a marked response to pemoline treatment relative to placebo on the ADHD rating scale (p = 0.001), with an average reduction of 3.02 points per week of treatment. Sixty percent of adolescents responded to pemoline, compared to 11% treated with placebo. This response was independent of gender or lifetime psychiatric comorbidity. Pemoline was well tolerated, with patients averaging 2.88 mg/kg/day in two doses per day, with a mean dose at end of follow-up of 181.1 mg (SD 45.6, range112.5-262.5 mg). Side effects were mild, and no adverse hepatic events occurred. Conclusions: These findings resemble those reported in children and adultswith ADHD. This trial suggests pemoline is well tolerated and effective inadolescents and may be a particularly useful ADHD treatment for adolescents.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 01/04/20 alle ore 20:59:30